

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Versant Venture Capital VI, L.P.</u> <hr/> (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 <hr/> (Street) SAN FRANCISCO CA 94104 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oyster Point Pharma, Inc. [OYST]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/21/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/21/2021		j ⁽¹⁾		200,213	D	\$0.00	614,820	I	See Footnotes ⁽²⁾
Common Stock	12/21/2021		j ⁽³⁾		51,556	A	\$0.00	51,556	I	See Footnotes ⁽⁴⁾
Common Stock	12/21/2021		j ⁽⁵⁾		51,556	D	\$0.00	0	I	See Footnotes ⁽⁴⁾
Common Stock	12/21/2021		j ⁽⁶⁾		1,261	D	\$0.00	3,726	I	See Footnotes ⁽⁷⁾
Common Stock								2,236,888	D ⁽⁸⁾	
Common Stock								1,003,658	I	See Footnotes ⁽⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.

 (Last) (First) (Middle)
 ONE SANSOME STREET
 SUITE 3630

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Versant Ventures VI GP, L.P.

 (Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Versant Ventures VI GP-GP, LLC](#)

(Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Versant Vantage I, L.P.](#)

(Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Versant Vantage I GP, L.P.](#)

(Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Versant Vantage I GP-GP, LLC](#)

(Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Versant Ventures IV, LLC](#)

(Last) (First) (Middle)

ONE SANSOME STREET
SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Venture Capital IV, L.P.		
(Last)	(First)	(Middle)
ONE SANSOME STREET		
SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Versant Side Fund IV, L.P.		
(Last)	(First)	(Middle)
ONE SANSOME STREET		
SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)

Explanation of Responses:

- Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("Versant IV") to its partners pursuant to a Rule 10b5-1 trading plan.
- Shares held by Versant IV. Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of Versant IV. William J. Link, a member of the Issuer's board of directors, is a managing member of Versant Ventures IV and may be deemed to share voting and dispositive power over the shares held by Versant IV. Each of Versant Ventures IV and William J. Link disclaims beneficial ownership of the shares held by Versant IV, except to the extent of their respective pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly, files separate Section 16 reports.
- Represents a change in the form of ownership of Versant Ventures IV by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant IV.
- Shares held by Versant Ventures IV. William J. Link, a member of the Issuer's board of directors, is a managing member of Versant Ventures IV and may be deemed to share voting and dispositive power over the shares held by Versant Ventures IV. William J. Link disclaims beneficial ownership of the shares held by Versant Ventures IV, except to the extent of his pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly files separate Section 16 reports.
- Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures IV to its members.
- Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to its partners pursuant to a Rule 10b5-1 trading plan.
- Shares held by Versant Side Fund IV. Versant Ventures IV is the sole general partner of Versant Side Fund IV. William J. Link, a member of the Issuer's board of directors, is a managing member of Versant Ventures IV and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund IV. Each of Versant Ventures IV and William J. Link disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of their respective pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly, files separate Section 16 reports.
- Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and Clare Ozawa disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.
- Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and Clare Ozawa disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.

Remarks:

[/s/ Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner](#)
[By: Versant Ventures VI GP- GP, LLC Its: General Partner](#)
[By: Robin L. Praeger Its: Managing Director](#)
[/s/ Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC Its: General Partner](#)
[By: Robin L. Praeger Its: Managing Director](#)
[/s/ Versant Ventures VI GP- GP, LLC By: Robin L. Praeger](#)
[Its: Managing Director](#)
[/s/ Versant Vantage I, L.P. By: Versant Vantage I GP, L.P. Its: General Partner](#)
[By: Versant Vantage I GP-GP, LLC Its: General Partner](#)
[By: Robin L. Praeger Its: Managing Director](#)
[/s/ Versant Vantage I GP, L.P. By: Versant Vantage I GP-GP,](#)

LLC Its: General Partner By:
Robin L. Praeger Its:
Managing Director
/s/ Versant Vantage I GP-GP,
LLC By: Robin L. Praeger Its: 12/23/2021
Managing Director
/s/ Versant Ventures IV, LLC
By: Robin L. Praeger Its: 12/23/2021
Managing Director
/s/ Versant Venture Capital IV,
L.P. By: Versant Ventures IV,
LLC Its: General Partner By: 12/23/2021
Robin L. Praeger Its:
Managing Director
/s/ Versant Side Fund IV, L.P.
By: Versant Ventures IV, LLC
Its: General Partner By: Robin 12/23/2021
L. Praeger Its: Managing
Director

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.